NASDAQ · VTGN
Healthcare · Biotechnology
$0.24
Down-$0.01 (-2.33%)
Updated Sep 16, 2026, 10:27 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VTGN closed at $0.24 after 20 trading sessions, down 2.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.246 | $0.2468 | $0.2361 | $0.2361 | 194.44K |
| Sep 14, 2026 | $0.249 | $0.2497 | $0.2418 | $0.2432 | 239.36K |
| Sep 11, 2026 | $0.2399 | $0.245 | $0.2325 | $0.237 | 309.99K |
| Sep 10, 2026 | $0.238 | $0.2442 | $0.2347 | $0.239 | 341.1K |
| Sep 9, 2026 | $0.2416 | $0.2464 | $0.23 | $0.2355 | 801.74K |
| Sep 8, 2026 | $0.25 | $0.25 | $0.24 | $0.2434 | 321.45K |
| Sep 4, 2026 | $0.2462 | $0.2584 | $0.2425 | $0.2428 | 347.26K |
| Sep 3, 2026 | $0.2513 | $0.255 | $0.2412 | $0.2462 | 256.58K |
| Sep 2, 2026 | $0.24 | $0.2539 | $0.24 | $0.246 | 197.89K |
| Sep 1, 2026 | $0.2473 | $0.2514 | $0.24 | $0.2433 | 596.32K |
| Aug 31, 2026 | $0.258 | $0.26 | $0.2434 | $0.255 | 467.38K |
| Aug 28, 2026 | $0.2569 | $0.2589 | $0.246 | $0.2529 | 449.67K |
| Aug 27, 2026 | $0.2599 | $0.269 | $0.2529 | $0.257 | 341.22K |
| Aug 26, 2026 | $0.2515 | $0.269 | $0.2421 | $0.26 | 569.37K |
| Aug 25, 2026 | $0.245 | $0.252 | $0.2401 | $0.2484 | 712.92K |
| Aug 24, 2026 | $0.2394 | $0.2481 | $0.2355 | $0.2438 | 477.88K |
| Aug 21, 2026 | $0.239 | $0.2542 | $0.2367 | $0.244 | 990.78K |
| Aug 20, 2026 | $0.2461 | $0.249 | $0.233 | $0.2411 | 705.69K |
| Aug 19, 2026 | $0.2456 | $0.252 | $0.237 | $0.2441 | 404.92K |
| Aug 18, 2026 | $0.2535 | $0.2673 | $0.2415 | $0.242 | 2.3M |
The latest Smart Investors Daily articles mentioning VTGN.
VTGN research
Company profile and research snapshot.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 17, 2025 | Maxim Group | Hold | — |
| Dec 17, 2025 | Jefferies | Hold | — |
| Dec 17, 2025 | William Blair | Market Perform | — |
| Dec 7, 2023 | Jefferies | Buy | — |
| Nov 14, 2023 | Stifel | Buy | — |
No generated briefing is available yet.
Finnhub · May 14, 2026
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...
Finnhub · May 12, 2026
VistaGen Therapeutics Inc: Vistagen announces preliminary positive data in ongoing open-label extension portion of PALISADE-3 phase 3 study of fasedienol for the acute treatment of social anxiety...
Benzinga · May 12, 2026
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
Finnhub · May 11, 2026
SOUTH SAN FRANCISCO - Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTGN.
